1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Regulation

Brazilian Medtech Welcomes Parametric Release Sterilization Regime

 
• By Bernard Murphy

Brazil has approved a long-awaited reform of its medical device sterilization protocols, with the adoption of a parametric release regime – a move which the industry has welcomed as “putting an end to a significant barrier” to local medical technology business.

BrazilMap_1200x675

Brazil's medical technology regulatory agency, Anvisa, has enacted Regulation RDC 291, of 24 June 2019, enabling, with immediate effect, new devices sterilized using ethylene oxide to be certified as sterile under a parametric release protocol (subject to standards ABNT NBR ISO 11135:2018) or using biological markers. Parametric release essentially relies on progressive stages of sterilization instead of a series of final sterility tests.

Until now, under Ordinance (Portaria Interministerial) 482, of April 1999, which RDC 291/2019 replaces, both biological marker and sterility tests...

More from Regulation

HealthAI: ‘Established Regulations Already Exist For Regulating AI In Healthcare Safely’

 
• By Natasha Barrow

Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.

EUDAMED Notice Anticipated By September As Commission Optimizes Operations

 
• By Amanda Maxwell

The last steps are taking place leading to the launch of the EU’s medical device database, EUDAMED.

Commission Decision Launches Pediatric And Rare Disease Expert Group

 
• By Amanda Maxwell

A revised annex to the original decision also outlines expert remuneration limits and introduces further changes.

Dermal Fillers For Décolletage May Gain FDA Approval

 
• By Elizabeth Orr

An upcoming US FDA advisory panel meeting will discuss adding a new indication to allow dermal fillers to be used in the upper chest, or décolletage. Plastic surgeons expect this could drive interest in the procedure, which is already performed off-label.

More from Policy & Regulation